A Phase III, Multicenter, Randomized Study Of Atezolizumab (Anti-PD-L1 Antibody) In Combination With Enzalutamide Versus Enzalutamide Alone In Patients With Metastatic Castration Resistant Prostate Cancer After Failure Of An Androgen Synthesis Inhibitor A

Protocol: 
AAAR1589
Phase: 
III

A Phase III, Multicenter, Randomized Study Of Atezolizumab (Anti-PD-L1 Antibody) In Combination With Enzalutamide Versus Enzalutamide Alone In Patients With Metastatic Castration Resistant Prostate Cancer After Failure Of An Androgen Synthesis Inhibitor A

This study will evaluate the efficacy, safety, and pharmacokinetics of atezolizumab with enzalutamide compared with enzalutamide in patients with metastatic castration-resistant prostate cancer (CRPC).

Specialty Area(s)

Immunotherapy